With the recent approvals of CAR-T for second-line therapy in myeloma, does this change your approach to use of consolidative autologous transplant or autologous transplant as second line therapy?
2 Answers
Mednet MemberInvited Expert
Medical Oncology · University of Washington, Fred Hutchinson Cancer Research Center
Answered on
This is an excellent two-part question, and hopefully one where we'll continue to see more data year by year!
The second question (ASCT as second-line therapy) is easier to answer - in brief, I no longer recommend this. Extrapolating from first-line consolidation to second-line salvage ASCT (i.e., f...
The second question (ASCT as second-line therapy) is easier to answer - in brief, I no longer recommend this. Extrapolating from first-line consolidation to second-line salvage ASCT (i.e., f...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · OhioHealth
Answered on
In the first-line therapy for newly diagnosed multiple myeloma, the data support autologous SCT as consolidation after induction therapy even in the era of novel therapy (DETERMINATION trial, Richardson et al., PMID 35660812) with median PFS 67.5 mos SCT vs 46.2 mos VRd after a med FU of 76 mos. The...
Join for free or sign in to see the full answer